Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicity

Biochemistry and Cell Biology

Volumn 85, Issue 2, 2007, Pages 196-202

  Yang, Zhang Min ^a,b   Li, En Min ^a   Lai, Bao Chang ^b   Wang, Yi Li ^b   Si, Lu Sheng ^b  

^a SHANTOU UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Anti CD3 scFv; B7.1; Biological activity; Eukaryotic expression; Fusion protein; HeLa cells

Indexed keywords

BIOTHERAPY; ELECTROPORATION; EUKARYOTIC EXPRESSION; HELA CELLS;

BIOACTIVITY; BIOASSAY; CELL CULTURE; CELLS; CYTOTOXICITY; GENE ENCODING;

PROTEINS;

ANTIBODY; BROMINE DERIVATIVE; CD3 SCFV ANTIBODY; HYBRID PROTEIN; PROTEIN; PROTEIN B7.1; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ELECTROPORATION; EXPRESSION VECTOR; FUSION GENE; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD80; HELA CELLS; HUMANS; LYMPHOCYTE ACTIVATION; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EUKARYOTA; MAMMALIA;

EID: 34249675795     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/O07-013     Document Type: Conference Paper

References (32)

1. Antonia, S.J. 1999. B7-1 gene-modified tumor cell vaccines. Curr. Opin. Mol. Ther. 1: 50-56.
2. Biburger, M., Weth, R., and Weis, W.S. 2005. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/ HER2. J. Mol. Biol. 346: 1299-1311. doi:10.1016/j.jmb.2004. 12.052.
3. Bolhuis, R.L., Sturm, E., and Braakman, E. 1991. T cell targeting in cancer therapy. Cancer Immunol. Immunother. 34: 1-8. doi:10.1007/ BF01741317.
4. Boon, T., and Van den Eynde, B. 2003. Tumour immunology. Curr. Opin. Immunol. 15: 129-130. doi:10.1016/S0952-7915(03)00010-4.
5. Bretscher, P. 1992. The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today, 13: 74-76. doi:10. 1016/0167-5699(92)90138-W.
6. Challita-Eid, P.M., Penichet, M.L., Shin, S.U., Poles, T., Mosammaparast, N., Mahmood, K., et al. 1998. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J. Immunol. 160: 3419-3426.
7. Chiu, S.J., Ueno, N.T., and Lee, R.J. 2004. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J. Control. Release, 97: 357-369. doi:10.1016/j.jconrel.2004.03.019.
8. de Ines, C., Cochlovius, B., Schmidt, S., Kipriyanov, S., Rode, H.J., and Little, M. 1999. Apoptosis of a human melanoma cell line specifically induced by membrane-bound single-chain antibodies. J. Immunol. 163: 3948-3956.
9. Dermime, S., Gilham, D.E., Shaw, D.M., Davidson, E.J., Meziane, K., Armstrong, A., Hawkins, R.E., and Stern, P.L. 2004. Vaccine and antibody-directed T cell tumour immunotherapy. Biochim. Biophys. Acta, 1704: 11-35.
10. Dreier, T., Lorenczewski, G., Brandi, C., Hoffmann, P., Syring, U., Hanakam, F., et al. 2002. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer, 100: 690-697. doi:10.1002/ijc.10557.
11. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998. doi:10.1038/ni1102-991.
12. Foss, F.M. 2002. Immunologic mechanisms of antitumor activity. Semin. Oncol. 29: 5-11. doi:10.1053/sonc.2002.33076.
13. Fukazawa, T., Maeda, Y., Durbin, M.L., Nakai, T., Matsuoka, J., Tanaka, H., Naomoto, Y., and Tanaka, N. 2007. Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system. Mol. Cancer Ther. 6: 244-252. doi:10.1158/1535-7163.MCT-06-0408.
14. Gabrilovich, D., and Pisarev, V. 2003. Tumor escape from immune response: mechanisms and targets of activity. Curr. Drug Targets, 4: 525-536. doi: 10.2174/1389450033490849.
15. Henning, P., Andersson, K.M., Frykholm, K., Ali, A., Magnusson, M.K., Nygren, P.A., et al. 2005. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther. 12: 211-224. doi:10.1038/sj. gt.3302408.
16. Heo, D.S., Park, J.G., Hata, K., Day, R., Herberman, R.B., and Whiteside, T.L. 1990. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res. 50: 3681-3690.
17. Hoffmann, P., Mueller, N., Shively, J.E., Fleischer, B., and Neumaier, M. 2001. Fusion proteins of B7.1 and a carcinoembryonic antigen (CEA)-specific antibody fragment opsonize CEA-expressing tumor cells and coactivate T-cell immunity. Int. J. Cancer, 92: 725-732. doi:10.1002/1097-0215(20010601) 92:5〈725::AID-IJC1252〉3.0.CO;2-S.
18. Horton, R.M., Hunt, H.D., Ho, S.N., Pullen, J.K., and Pease, L.R. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene, 77: 61-68. doi:10.1016/0378-1119(89)90359-4.
19. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., et al. 1995. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. 55: 3105-3109.
20. Indiveri, F., Huddlestone, J., Pellegrino, M.A., and Ferrone, S. 1980. Isolation of human T lymphocytes: comparison between nylon wool filtration and rosetting with neuraminidase and 2-aminoethylisothiouronium bromide (AET)-treated sheep red blood cells (SRBC). J. Immunol. Methods, 34: 107-115. doi:10. 1016/0022-1759(80)90164-7.
21. Jost, C.R., Titus, J.A., Kurucz, I., and Segal, D.M. 1996. A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL. Mol. Immunol. 33: 211-219. doi:10.1016/0161-5890(95)00087- 9.
22. Kufer, P., Mack, M., Gruber, R., Lutterbuse, R., Zettl, F., and Riethmuller, G. 1997. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol. Immunother. 45: 193-197. doi:10.1007/s002620050431.
23. Liao, K.W., Lo, Y.C., and Roffler, S.R. 2000. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Ther. 7: 339-347. doi:10.1038/sj.gt.3301080.
24. Martin-Fontecha, A., Moro, M., Crosti, M.C., Veglia, F., Casorati, G., and Dellabona, P. 2000. Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity. J. Immunol. 164: 698-704.
25. Mocellin, S., Rossi, C.R., and Nitti, D. 2004. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp. Cell Res. 299: 267-278. doi:10.1016/j.yexcr.2004.06. 017.
26. Qian, Z.M., Li, H., Sun, H., and Ho, K. 2002. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54: 561-587. doi:10.1124/pr.54.4.561.
27. Seliger, B., Maeurer, M.J., and Ferrane, S. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol. Today, 21: 455-464. doi:10.1016/S0167-5699(00)01692-3.
28. Shen, W., Wang, Y., Geng, Y., and Si, L. 2000. Bacterially produced human B7.1 protein encompassing its complete extracellular domain maintains its costimulatory activity in vitro. Chin. Med. J. (Engl.), 113: 714-719.
29. Vesosky, B., and Hurwitz, A.A. 2003. Modulation of costimulation to enhance tumor immunity. Cancer Immunol. Immunofher. 52: 663-669. doi:10.1007/s00262-003-0424-5.
30. Ward, S., Casey, D., Labarthe, M.C., Whelan, M., Dalgleish, A., Pandha, H., and Todryk, S. 2002. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51: 351-357. doi:10.1007/s00262-002-0286-2.
31. Weis, W., Biburger, M., Muller, T., Dalken, B., Giesubel, U., Tonn, T., and Uherek, C. 2004. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer Immunol. Immunother. 53: 217-226. doi:10.1007/s00262-003-0482-8.
32. Yu, X., Abe, R., and Hodes, R.J. 1998. The role of B7-CD28 co-stimulation in tumor rejection. Int. Immunol. 10: 791-797. doi:10.1093/intimm/10.6. 791.